| Title | Induction chemotherapy followed by camrelizumab plus apatinib and chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, single-arm trial |
|---|---|
| Description | Chemo-immunotherapy is the current first-line treatment in patients with extensive-stage small cell lung cancer (ES-SCLC), but survival benefits are modest. We aimed to evaluate the safety, antitumor activity and biomarkers of first-line camrelizumab and apatinib plus chemotherapy in untreated ES-SCLC patients. In this single-arm trial, eligible patients received 2 cycles of etoposide and carboplatin as induction treatment followed by 2-4 cycles of camrelizumab, apatinib plus EC, then maintenance camrelizumab plus apatinib. Primary endpoint was safety. Secondary endpoints included objective response rate (ORR), duration of response, progression-free survival, and overall survival. Targeted sequencing and whole transcriptome sequencing were performed to explore biomarkers. |
| Organism | Homo sapiens |
| Data Type | Expression Profiling |
| Data Accessibility | Controlled-access |
| BioProject | PRJCA035154 |
| Release Date | 2025-02-25 |
| Submitter | Chengzhi Zhou (doctorzcz@163.com) |
| Organization | First Affiliated Hospital of Guangzhou Medical University |
| Submission Date | 2025-01-16 |
The data cannot be downloaded as it has not yet been registered in the Human Genetic Resource Management Platform of MOST.
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download |
|---|---|---|---|---|---|---|
| OMIX008707-01 | WTS_detection_sample21.txt | 21 | Expression Profiling | 4.8 MB | txt | Unavailable |
| Paper Title | Journal Name | Publish Time | Accession | Citing Type |
|---|---|---|---|---|
| Induction chemotherapy followed by camrelizumab plus apatinib and chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: a multicenter … | Signal Transduction and Targeted Therapy | 2025-02 | OMIX008707 | Deposit |